Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
414,602 | 427,687 | 304,399 | 231,789 | 122,977 |
Cost of Goods Sold (COGS) incl. D&A |
30,169 | 20,145 | 21,843 | 12,298 | 10,915 |
COGS excluding D&A |
20,391 | 10,816 | 12,426 | 3,882 | 2,989 |
Depreciation & Amortization Expense |
9,778 | 9,329 | 9,417 | 8,416 | 7,926 |
Gross Income |
384,433 | 407,542 | 282,556 | 219,491 | 112,062 |
SG&A Expense |
238,763 | 205,178 | 195,078 | 197,290 | 157,464 |
Research & Development |
181,024 | 158,295 | 147,373 | 138,862 | 129,041 |
Other SG&A |
57,739 | 46,883 | 47,705 | 58,428 | 28,423 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
0 | 0 | 0 | NA | 0 |
Non Operating Income/Expense |
0 | 0 | 0 | 0 | 799 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
11,495 | 11,413 | 11,236 | 11,160 | 9,455 |
Gross Interest Expense |
11,495 | 11,413 | 11,236 | 11,160 | 9,455 |
Pretax Income |
134,559 | 191,468 | 76,743 | 11,651 | -54,058 |
Income Tax |
-335,848 | 0 | 0 | 0 | -615 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
470,407 | 191,468 | 76,743 | 11,651 | -53,443 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
470,407 | 191,468 | 76,743 | 11,651 | -53,443 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
470,407 | 191,468 | 76,743 | 11,651 | -53,443 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
470,407 | 191,468 | 76,743 | 11,651 | -53,443 |
Operational EPS |
4.08 | 1.65 | 0.70 | 0.11 | -0.59 |
EPS (basic) |
4.92 | 2.02 | 0.81 | 0.12 | -0.59 |
EBITDA |
155,448 | 211,693 | 96,895 | 30,617 | -37,476 |
Depreciation & Amortization Expense |
9,778 | 9,329 | 9,417 | 8,416 | 7,926 |
Common Shares Outstanding |
122,434 | 115,830 | 110,167 | 107,734 | 90,610 |
Basic Shares Outstanding |
95,611 | 95,012 | 94,589 | 93,446 | 90,610 |
Diluted Shares Outstanding |
122,434 | 115,830 | 110,167 | 107,734 | 90,610 |
Diluted EPS after Extraordinary Items |
4.08 | 1.65 | 0.70 | 0.11 | -0.59 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
4.92 | 2.02 | 0.81 | 0.12 | -0.59 |
*Figures in thousands of U.S. Dollars except shares outstanding.
